Hungarian start-up Solvo Biotechnology is attempting to create therapeutics to treat multidrug resistance--a phenomenon describing a cancer cell's ability to resist the toxicity of chemotherapies. Solvo is developing compounds targeting molecular pumps that expel cytotoxic drugs from cancerous cells.

Boehringer Ingelheim has restructured to emphasize partnering--both to bring in new products and technologies, and to boost its global market share. The strategy is paying off.

Drug Discovery Tools; Genomics. Jouvence is dedicated to developing anti-aging therapies through genomics efforts. The company has licensed the LAG-1 gene, one of the first genes definitively linked to the longevity of an organism. Yeast strains in which the gene has been knocked out live 100% longer than average.